HLA Class II Restriction of Autoreactive T Cell Responses in Pemphigus Vulgaris: Review of the Literature and Potential Applications for the Development of a Specific Immunotherapy

References

• Stanley J. R. Pemphigus and pemphigoid as paradigms of organ-specific autoimmune diseases. J. Clin. Invest 1989; 83: 1443–1448
   PubMed Web of Science ®Google Scholar
• Amagai M., Klaus-Kovtun V., Stanley J. R. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869–877
   PubMed Web of Science ®Google Scholar
• Amagai M., Karpati S., Prussick R., Klaus-Kovtun V., Stanley J. R. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin. Invest 1992; 90: 919–924
   PubMed Web of Science ®Google Scholar
• Jones C. C., Hamilton R. G., Jordon R. E. Subclass distribution of human IgG autoantibodies in pemphigus. Clin. Immunol 1988; 8: 43–49
   Google Scholar
• Bhol K. A., Mohimen A., Ahmed A. R. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994; 189(Suppl. 1)85–89, Basel
   PubMed Web of Science ®Google Scholar
• Bhol K., Ahmed A. R., Aoki V., Mohimen A., Nagarwalla N., Natarajan K. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc. Natl. Acad. Sci. USA 1995; 92: 5239–5243
   PubMed Web of Science ®Google Scholar
• Hashimoto T., Amagai M., Watanabe K., Dmochowski M., Chidgey M. A.J., Yuc K. K.M., Garrod D. R., Nishikawa T. A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsgl and Dsg3) and desmocollins. J. Invest. Dermatol 1995; 104: 541–544
   PubMed Web of Science ®Google Scholar
• Emery D. J., Diaz L. A., Fairly J. A., Lopez A., Taylor A. F., Giudice G. J. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglcin 1. J. Invest. Dermatol 1995; 104: 323–328
   PubMedGoogle Scholar
• Bedane C., Prost C., Thomine E., Intrator L., Joly P., Caux F., Blecker M., Bernard P., Leboutet M. J., Tron F., Lauret P., Bonnetblanc J. M, Dubertret L. Binding of autoantibodies is not restricted to desmosomes in pemphigus vulgaris: comparison of 14 cases of pemphigus vulgaris and 10 cases of pemphigus foliaceus studied by Western immunoblot and immunoelectron microscopy. Arch. Dermatol. Res. 1996; 288: 343–352
   PubMed Web of Science ®Google Scholar
• Joly P., Raux G., Thomine E., Lauret P., Tron F. Intracellular and extracelleular epidermal antigens arc recognized by different IgG subclass in autoimmune bullous skin diseases. J. Invest. Dermatol 1998; 110: 511 A
   Google Scholar
• Nguyen V. T., Ndoye A., Shultz L. D., Grando S. A. Binding of pemphigus antibodies to the epidermis of mice lacking desmoglein 3. J. Invest. Dermatol 1998; 110: 506A
   Google Scholar
• Nguyen V. T., Lee T. X., Ndoye A., Shultz L. D., Pittelkow M. R., Dahl M. V., Lynch P. J., Grando S. A. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Arch. Dermatol 1998; 134: 971–980
   PubMedGoogle Scholar
• Huilgol S. C., Black M. M. Management of the immunobullous disorders. II. Pemphigus. Clin. Exp. Dermatol 1995; 20: 283–293
   PubMedGoogle Scholar
• Korman N. Pemphigus. J. Am. Acad. Dermatol 1988; 18: 1219–1238
   PubMed Web of Science ®Google Scholar
• Rose N. R. Current concepts of autoimmune diseases. Transplant. Proc 1988; 20(Suppl. 4)3–10
   PubMedGoogle Scholar
• Martin R., Howell M. D., Jaraquemada D., Flerlage M., Richert J., Brostoff S., Long E. O., McFarlin D. E., McFarland H. F. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 1991; 173: 19–24
   PubMed Web of Science ®Google Scholar
• Pettc M., Fujita K., Wikinson D., Altmann D. M., Trowsdale J., Giergcrich G., Hinkkanen A., Epplen T. J., Kappos L., Wekerle H. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. USA, 87: 7968–7972
   PubMedGoogle Scholar
• Brocke S., Brautbar C., Steinman L. In vitro, proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to MHC class II genes. J. Clin. Invest 1988; 82: 1894–1900
   PubMedGoogle Scholar
• Manfredi A. A., Yuen M. H., Moiola L., Protti M. P., Conti-Tronconi B. M. Human acetylcholine receptor presentation in myasthenia gravis. DR restriction of autoimmune T epitopes and binding of synthetic receptor sequences to DR molecules. J. Immunol 1994; 152: 4165–4174
   PubMedGoogle Scholar
• Rossini A. A., Mordes J. P., Like A. A. Immunology of insulin-dependent diabetes mellitus. Annu. Rev. Immunol 1985; 3: 289–295
   PubMed Web of Science ®Google Scholar
• Kaufmann D. L., Erlander M. G., Clare-Salzler M., Atkinson M. A., Maclaren N. K., Tobin A. J. Autoimmunity to two forms of glutamatc decarboxylase in insulin-dependent diabetes mellitus. J. Clin. Invest 1992; 89: 283–292
   PubMedGoogle Scholar
• Lohmann T., Leslie R. D.G., Hawa M., Geysen M., Rodda S. J., Londei M. Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus. Lancet 1994; 343: 1607–160
   PubMed Web of Science ®Google Scholar
• Tan P. L., Farmiloe S., Young J., Watson J. D., Skinner M. A. Lymphocyte responses to DR4/1-restricted peptides in rheumatoid arthritis. Arthr. Rheum 1992; 35: 1419–142
   PubMedGoogle Scholar
• Wucherpfennig K. W., Yu B., Bhol K., Monos D. S., Argyris E., Karr R. W., Ahmed A. R., Strominger J. L. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 1995; 92: 11935–11939
   PubMed Web of Science ®Google Scholar
• Lin M. S., Swartz S. J., Lopez A., Ding X., Fernandez-Vina M. A., Stastny P., Fairley J. A., Diaz L. A. Development and characterization of desmoglein 3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest 1997; 99: 31–40
   PubMed Web of Science ®Google Scholar
• Hertl M., Amagai M., Sundaram H., Stanley J., Ishii K., Katz S. I. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J. invest. Dermatol 1998; 110: 62–66
   PubMed Web of Science ®Google Scholar
• Ahmed A. R., Yunis E. J., Khatri K., Wagner R., Notani G., Awdeh Z., Alper C. A. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 1990; 87: 7658–7662
   PubMedGoogle Scholar
• Ahmed A. R., Wagner R., Khatri K., Notani G., Awdeh Z., Alper C. A., Yunis E. J. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. USA 1991; 88: 5056–5061
   PubMed Web of Science ®Google Scholar
• Niizeki H., Inoku H., Narimatsu H., Takata H., Sonoda A., Tadakuma T., Ando A., Tsuji K., Hashimoto T., Nishikawa T. HLA class II antigens are associated with Japanese pemphigus patients. Hum. Immunol 1991; 31: 246–250
   PubMed Web of Science ®Google Scholar
• Hertl M., Karr R. W., Amagai M., Katz S. I. Heterogenous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J. Invest. Dermatol 1998; 110: 388–392
   PubMed Web of Science ®Google Scholar
• Todd J. A., Acha-Orbea H., Bell J. l., Chao N., Fronek Z., Jacob C O., McDermott M., Sinha A. A., Timmermann M., Steinman L., McDevitt H. O. A molecular basis for MHC U-associated autoimmunity. Science 1988; 240: 1003–1009
   PubMed Web of Science ®Google Scholar
• Szafer F., Brautbar C., Tzfoni E., Frankel G., Sherman L., Cohen I., Hacham-Zadch S., Aberer W., Tappeiner G., Holubar K. Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQwl and DQw3 alleles of the HLA-D region. Proc. Natl. Acad. Sci. USA 1987; 84: 6542–6545
   PubMedGoogle Scholar
• Sinha A. A., Brautbar C., Szafer F., Friedmann A., Tzfoni E., Todd J. A., Steinman L., McDevitt H. O. A newly characterized HLA-DQβ allele associated with pemphigus vulgaris. Science 1988; 239: 1026–1029
   PubMed Web of Science ®Google Scholar
• Niizeki H., Inoko H., Mizuki N., Inamoto N., Hashimoto K., Hashimoto T., Nishikawa T. HLA-DQA1,-DQB1 and -DRB1 genotyping in Japanese pemphigus vulgaris patients by the PCR-RFLP method. Tissue Antigens 1994; 44: 248–251
   PubMedGoogle Scholar
• Gregerson P. K., Silver J., Winchester R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis. Rheum 1987; 30: 1205–121
   PubMed Web of Science ®Google Scholar
• Scharf S J., Long C M., Erlich H. A. Sequence analysis of the HLA-DRβ and HLA-DQβ loci from three pemphigus vulgaris patients. Hum. Immunol 1988; 22: 61–69
   PubMedGoogle Scholar
• Hammer J., Galazzi F., Bono E., Karr R. W., Guenot J., Valsasnini P., Nagy Z. A., Sinigaglia F. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp. Med. 1995; 181: 1847–185
   PubMed Web of Science ®Google Scholar
• O'Garra A., Steinman L., Gijbels K. CD4+ T cell subsets in autoimmunity. Curr. Opin. Immunol 1997; 9: 872–883
   PubMed Web of Science ®Google Scholar
• Garraud O., Nkenfou C., Bradley J. E., Perler F. B., Nutman T. B. Identification of recombinant filarial proteins capable of inducing polyclonal and antigen-specific IgE and IgG4 antibodies. L. Immunol 1995; 155: 1316–132
   Google Scholar
• Roitt I. M., Brostoff J., Male D. K. Immunology. Mosby-Year Book Europe Limited, London 1993
   Google Scholar
• Brown J. H., Jardetzky T. S., Gorga J. C, Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Atomic structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33–38
   PubMed Web of Science ®Google Scholar
• Stern L. J., Brown J. H., Jardetzky T. S., Gorga J. C., Urban R. G., Strominger J. L., Wiley D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215–219
   PubMed Web of Science ®Google Scholar
• Ghosh P., Amaya M., Mellins E., Wiley D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995; 378: 457–462
   PubMed Web of Science ®Google Scholar
• Wucherpfennig K. W., Strominger J. L. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp. Med. 1995; 181: 1597–1601
   PubMed Web of Science ®Google Scholar
• Sette A., Buus S., Colon S., Smith J. A., Miles C., Grey H. M. Structural characteristics of an antigen required for its interaction with la and recognition by T cells. Nature 1987; 328: 395–399
   PubMed Web of Science ®Google Scholar
• Rothbard J. B., Gefter M. L. Interactions between immunogenic peptides and MHC proteins. Annu. Rev. Immunol 1991; 9: 527–565
   PubMed Web of Science ®Google Scholar
• Hammer J., Sturniolo T., Sinigaglia F. HLA class II peptide binding specificity and autoimmunity. Adv. Immunol 1997; 66: 67–100
   PubMedGoogle Scholar
• Bodmer J. G., Marsh S. G.E., Albert E. D., Bodmer W. F., Dupont B., Erlich H. A., Mach B., Mayr W. R., Parham P., Sasazuki T., Schreuder G. M.Th., Strominger J. L., Svejgaard A., Terasaki P. I. Nomenclature for factors of the HLA system. 1994. Tissue Antigens 1994; 44: 1–18
   PubMed Web of Science ®Google Scholar
• Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv. Immunol 1994; 56: 289–466
   Google Scholar
• Korman A. J., Boss J. M., Spiess T., Sorrentino R., Okada K., Strominger J. L. Genetic complexibility and expression of human class II histocompatibility antigens. Immunol. Rev. 1985; 85: 45–53
   PubMedGoogle Scholar
• McKinney J. S., Fu X. T., Swearingen C., Klohe E., Karr R. W. Individual effects of the DR11-variable β-chain residues 67, 71. and 86 upon DR (alpha, β 1101)-restricted, peptide-specific T cell proliferation. J. Immunol 1994; 153: 5564–5571
   PubMedGoogle Scholar
• Kwok W. W., Ncpom G. T., Raymond F. C. HLA-DQ polymorphisms are highly selective for peptide binding interactions. J. Immunol 1995; 155: 2468–2476
   PubMed Web of Science ®Google Scholar
• Todd J. A., Bell J. L, McDevitt H. O. HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599–604
   PubMed Web of Science ®Google Scholar
• Heimberg H., Nagy Z. P., Somers G., DeLeeuw I., Schuit F. C. Complementation of HLA-DQA and -DQB genes confers susceptibility and protection to insulin-dependent diabetes mellitus. Hum. Immunol 1992; 33: 10–17
   PubMed Web of Science ®Google Scholar
• Nepom B. S., Nepom G. T., Coleman M., Kwok W. W. Critical contribution of β chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Proc. Nail. Acad. Sci. USA 1993; 93: 7202–7206
   Google Scholar
• Delgado J. C., Turbay D., Yunis E. J., Yunis J J., Morton E. D., Bhol K., Norman R., Alper C. A., Good R. A., Ahmed R. A common major histocompatibility complex class II allele HLA-DQβ 1 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. USA 1996; 93: 8569–8571
   PubMedGoogle Scholar
• Büdinger L., Borradori L., Yee C., Eming R., Fercncik S., Grosse-Wilde H., Merk H. F., Yancey K., Hertl M. Identification and characterization of autoreactive T cell responses to bullous pemphigoid (BP) antigen 2 in patients with BP and HLA-DQβ 1*0301 positive normals. J. Clin. Invest 1998; 102: 2082–2089
   PubMed Web of Science ®Google Scholar
• McRae B. L., Vanderlugt C. L., DalCanto M. C., Miller S. D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995; 182: 75–85
   PubMed Web of Science ®Google Scholar
• Miller S. D., McRae B. L., Vanderlugt C. L., Nikcevich M., Pope J. G., Karpus W. J. Evolution of the T cell repertoire during the course of immune-mediated de-myclinating diseases. Immunological reviews 1995; 144: 225–244
   PubMed Web of Science ®Google Scholar
• Link H., Xu Z. Y., Melms A., Kalbacher H., Sun J. B., Wang Z. Y., Fredriksson S., Olsson T. The T cell repertoire in myasthenia gravis involves multiple cholinergic receptor epitopes. Scand., J Immunol 1992; 36: 405–414
   PubMed Web of Science ®Google Scholar
• Lehmann H., Forsthuber T., Miller A., Sercarz E. E. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155–157
   PubMed Web of Science ®Google Scholar
• Röcken M., Shevach F. M. Immune deviation the third dimension of nondcletional T cell tolerance. Immunol. Rev. 1996; 149: 175–194
   PubMedGoogle Scholar
• Racke M. K., Bonomo A., Scott D. E., Cannella B., Levine A., Rainc C. S., Shevach E. M., Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 1994; 180: 1961–1966
   PubMed Web of Science ®Google Scholar
• Nicholson L. B., Greer J. M., Sobel R. A., Lees M. B., Kuchroo V. K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397–405
   PubMed Web of Science ®Google Scholar
• Del Prete G., Maggi E., Paola P., Chretien A., Tiri A., Macchia D., Banchereau J., Dc Vries J. E., Romagnani S. II-4 is an essential factor for the IgE synthesis induced in vitro, by human T cell clones and their supernatants. J. Immunol 1988; 140: 4193–4198
   PubMed Web of Science ®Google Scholar
• Akdis C. A., Blesken T., Akdis M., Wüthrich B., Blaser K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest 1998; 102: 98–106
   PubMed Web of Science ®Google Scholar
• Martinez-Soria E., Steinle V., Burkhardt C., Bcffy P., Tiercy J. M., Epplen J. T., Mach B., Trie C. An HLA-DRB α-helix motif shared by DR11 and DR8 alleles is implicated in the pluriallelic restriction of peptide-specific T cell lines. Human. Immunol 1994; 40: 279–290
   PubMedGoogle Scholar